Success or failure in drug development goes back to the early stages of drug discovery. In a series of webinars conducted together with the Division of Pharmacy Professional Development at the University of Wisconsin, we would like to discuss with you todays challenges, oppurtunities and state-of-the art technologies in early drug discovery. In the first installment of the series, W. Adam Hill will give an insight into the challenges and limitations researchers are facing in early drug discovery.
In this webinar Matthias Trost shows how the drug discovery process can be accelerated beyond conventional technologies with advanced mass spectrometry technology.
In this webinar of the Bruker-DPPD webinar series, Melanie Leveridge will discuss how the MALDI-TOF works in a real life pharmaceutical application. Real pharma examples and application vignettes are presented by a pharmaceutical Company Researcher (e.g. GSK) using automated MALDI-TOF to push back the boundaries and limits of conventional methods. This should be the message which validates the arguments and assertions made earlier.
Melanie Leveridge
Head, Screening Profiling and Mechanistic Biology, UK at GSK
Matthias Trost
Professor of Proteomics at Newcastle University
Adam Hill
CTO at Triple Sharp Venture Engineering
For Research Use Only. Not for use in clinical diagnostic procedures.